My cart
In the shopping cart is not goods, to choose and buy!
  • Product Name
  • Size
  • Quantity
  • Amount
    Selected items : 0 pieces Total : CHECK OUT()
    Etodolac (AY-24236)
    Etodolac (AY-24236)

    Market Price:

    This product is for research use only, not for human use. We do not sell to patients.
    Number: - + Pieces(InventoryPieces)
    InvivoChem Cat #: V1052
    CAS #: 41340-25-4Purity ≥98%

    Description: Etodolac (AY-24236, Etodolic Acid, AY24,236, AY24236, Lodine, Ramodar, Ultradol) is a potent nonsteroidal anti-inflammatory drug (NSAID) and a non-selective COX inhibitor with potential anti-inflammatory activity. It has been approved for the treatment of inflammation and pain. Etodolac was able to abolish the cell size decrease and block caspase-3/7 activity in TNFα-induced isolated rabbit articular chondrocytes. However, studies have shown that etodolac at 24h could induce cell death in human malignant rhabdoid tumor cells (FRTK-1) in a dose-dependent manner. Additionally, etodolac has shown to increase caspase-8, -9 and -3 activity 3 at 24 or 48 h in FRTK-1.

    References: Int J Mol Sci. 2013 Sep 30;14(10):19705-15; J Pharmacol Exp Ther. 2012 Jul;342(1):53-60.

    Customer Validation
    Official Supplier of
    • VE
    • OF
    • YALE
    • hhmi
    • 香港大学
    Publications Citing InvivoChem Products
    • Physicochemical and Storage Information
    • Protocol
    • Quality Control Documentation
    • Related Biological Data
    • Customer Review
    Molecular Weight (MW)287.35 
    CAS No.41340-25-4 
    Storage-20℃ for 3 years in powder form
    -80℃ for 2 years in solvent
    Solubility (In vitro)DMSO: 58 mg/mL (201.8 mM)
    Water: <1 mg/mL
    Ethanol: 58 mg/mL (201.8 mM)
    Other info

    Chemical Name: (RS)-2-(1,8-Diethyl-4,9-dihydro-3H-pyrano[3,4-b]indol-1-yl)acetic acid


    InChi Code: InChI=1S/C17H21NO3/c1-3-11-6-5-7-12-13-8-9-21-17(4-2,10-14(19)20)16(13)18-15(11)12/h5-7,18H,3-4,8-10H2,1-2H3,(H,19,20)


    SynonymsAY 24,236, Lodine, AY24,236, AY24236, Etodolic Acid, AY 24236, AY-24,236, AY-24236, Ramodar, Ultradol

    • Molarity Calculator
    • Dilution Calculator
    • The molarity calculator equation

      Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

      • Mass
      • Concentration
      • Volume
      • Molecular Weight *
      • =
      • ×
      • ×
    • The dilution calculator equation

      Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

      This equation is commonly abbreviated as: C1V1 = C2V2

      • Concentration (start)
      • ×
      • Volume (start)
      • =
      • Concentration (final)
      • ×
      • Volume (final)
      • ×
      • =
      • ×
      • C1
      • V1
      • C2
      • V2
    In Vitro

    In vitro activity: Etodolac markedly inhibits ICl, vol activation by TNFα as well as subsequent apoptotic events such as apoptotic cell volume decrease (AVD) and elevation of caspase-3/7 activity in isolated rabbit articular chondrocytes.

    In Vivo
    Etodolac attenuates paclitaxel-induced peripheral neuropathy by a COX-independent pathway in a mouse model of mechanical allodynia. Etodolac and other NSAIDs inhibits paw swelling and causes gastric mucosal lesions in adjuvant arthritic rats in a dose-dependent manner. Etodolac shows the highest UD(50) value and safety index among these NSAIDs in arthritic rats. Etodolac also shows the highest UD(50) value and safety index, except when its effects are assessed by acetic acid-induced writhing in normal rats. Etodolac dose-dependently inhibits the development of gastric cancer, and no cancer is detected at a dose of 30 mg/kg/day. Etodolac does not affect the extent of inflammatory cell infiltration or oxidative DNA damage, but it significantly inhibits mucosal cell proliferation and dose-dependently represses the development of intestinal metaplasia in the stomachs of Helicobacter pylori (Hp)-infected Mongolian gerbils (MGs). Etodolac alleviates heat-evoked hyperalgesia in the CCI rats and the increase in number of TRAP-positive multinucleated osteoclasts on the CCI-side is abrogated, however, it does not inhibit the decrease of bone mineral content (BMC) and bone mineral density (BMD) on the CCI-side. 
    Animal modelMice
    Formulation & Dosage30 mg/kg

    Int J Mol Sci. 2013 Sep 30;14(10):19705-15; J Pharmacol Exp Ther. 2012 Jul;342(1):53-60. 

    These protocols are for reference only. InvivoChem does not independently validate these methods.


      Home Prev Next Last page / pices


      Your information is safe with us. * Required Fields.
      Products are for research use only;  We do not sell to patients
      Tel: 1-708-310-1919
      Fax: 1-708-557-7486
      Subscribe to our E-newsletter
      • Name*
      • *
      • E-mail*
      • *
      • instructions:
      • *
      Copyright 2020 InvivoChem LLC | All Rights Reserved
      Do you confirm the receipt?